文献速递骨软组织肉瘤与黑色素瘤

达拉非尼联合曲美替尼治疗BRAFV600E突变肿瘤:NCI-MATCH H子方案结果

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
PubMed 文献 · J Clin Oncol · 2020-08-06

PURPOSE: BRAFV600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types.…

要点

  • 在经治的BRAFV600突变混合组织学肿瘤中,达拉非尼联合曲美替尼确认ORR达38%。
  • 中位PFS为11.4个月,中位OS为28.6个月,7种肿瘤类型中观察到缓解。
  • 不良反应与既往达拉非尼和曲美替尼已知安全性特征相当。

核心结论

  • 这种有前景的活性值得在目前已批准适应症之外的BRAFV600突变肿瘤中进一步研究。

研究设计与样本

  • EAY131-H是NCI-MATCH平台试验的H子方案,为开放标签、单臂研究。
  • 纳入携带BRAFV600突变的实体瘤、淋巴瘤或多发性骨髓瘤患者,排除黑色素瘤、甲状腺癌和结直肠癌患者,后续修正排除非小细胞肺癌患者。
  • 患者持续接受达拉非尼150 mg每日两次和曲美替尼2 mg每日一次治疗,直至疾病进展或不可耐受的毒性。
  • 主要终点为中心评估的客观缓解率(ORR);次要终点包括无进展生存期(PFS)、6个月PFS和总生存期。

主要发现

  • 中位PFS为11.4个月(90% CI 8.4至16.3个月)。
  • 在7种不同的肿瘤类型中观察到缓解。
  • 7例患者的缓解持续时间>12个月,其中4例>24个月;另有8例患者PFS>6个月。
  • 中位总生存期为28.6个月。

关键数值与推荐

  • 主要疗效分析人群(29例)的中位年龄为59岁,45%的患者接受过≥3线治疗。
  • 中位PFS为11.4个月(90% CI 8.4至16.3个月),中位OS为28.6个月。
  • 7例患者缓解持续时间>12个月,其中4例>24个月;8例患者PFS>6个月。

临床怎么用

  • 对于携带BRAFV600突变且已批准适应症之外的经治实体瘤、淋巴瘤或多发性骨髓瘤患者,达拉非尼联合曲美替尼显示出有前景的抗肿瘤活性。
  • 治疗期间不良反应与既往已知的达拉非尼和曲美替尼安全性特征相当。

局限性

  • 研究排除了黑色素瘤、甲状腺癌、结直肠癌患者,后续修正排除非小细胞肺癌患者,限制了结论在这些瘤种中的外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BRAFV600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with solid tumors, lymphomas, or multiple myeloma whose tumors harbored a BRAFV600 mutation. PATIENTS AND METHODS: EAY131-H is an open-label, single-arm study. Patients with melanoma, thyroid, or colorectal cancer were excluded; patients with non-small-cell lung cancer were later excluded in an amendment. Patients received dabrafenib 150 mg twice per day and trametinib 2 mg per day continuously until disease progression or intolerable toxicity. The primary end point was centrally assessed objective response rate (ORR); secondary end points included progression-free survival (PFS), 6-month PFS, and overall survival. RESULTS: Thirty-five patients were enrolled, and 29 were included in the primary efficacy analysis as prespecified in the protocol. Median age was 59 years, and 45% of the patients had received ≥ 3 lines of therapy. The confirmed ORR was 38% (90% CI, 22.9% to 54.9%) with P < .0001 against a null rate of 5%, and PFS was 11.4 months (90% CI, 8.4 to 16.3 months); responses were seen in 7 distinct tumor types. Seven patients had a duration of response of > 12 months, including 4 patients with a duration of response of > 24 months. An additional 8 patients had a PFS > 6 months. The median overall survival was 28.6 months. Reported adverse events were comparable to those noted in previously reported profiles of dabrafenib and trametinib. CONCLUSION: This study met its primary end point, with an ORR of 38% (P < .0001) in this mixed histology, pretreated cohort. This promising activity warrants additional investigations in BRAFV600-mutated tumors outside of currently approved indications.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol. 2020. PMID: 32758030. doi:10.1200/JCO.20.00762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。